Cargando…
c-Jun N-Terminal Kinase Phosphorylation Is a Biomarker of Plitidepsin Activity
Plitidepsin is an antitumor drug of marine origin currently in Phase III clinical trials in multiple myeloma. In cultured cells, plitidepsin induces cell cycle arrest or an acute apoptotic process in which sustained activation of c-Jun N-terminal kinase (JNK) plays a crucial role. With a view to opt...
Autores principales: | Muñoz-Alonso, María J., Álvarez, Enrique, Guillén-Navarro, María José, Pollán, Marina, Avilés, Pablo, Galmarini, Carlos M., Muñoz, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3707168/ https://www.ncbi.nlm.nih.gov/pubmed/23697951 http://dx.doi.org/10.3390/md11051677 |
Ejemplares similares
-
Plitidepsin: design, development, and potential place in therapy
por: Alonso-Álvarez, Sara, et al.
Publicado: (2017) -
Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
por: Galmarini, Carlos M., et al.
Publicado: (2014) -
Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin
por: Losada, Alejandro, et al.
Publicado: (2016) -
Plitidepsin for multiple myeloma
Publicado: (2019) -
Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis
por: Sachse, Martin, et al.
Publicado: (2022)